Condition: Myelodysplastic Syndrome · Sponsor: National Cancer Institute (NCI)
This phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasidenib in treating patients with higher-risk, IDH2-mutated myelodysplastic syndrome (MDS). ASTX727 is a combination of two drugs, decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Enasidenib is an enzyme inhibitor that may stop the growth of cells by blocking some of the enzymes needed for cell growth. Giving ASTX727 in combination with enasidenib may be effective in treating patients with higher-risk IDH2-mutated MDS.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Alta Bates Summit Medical Center-Herrick Campus | Berkeley, California, United States | Recruiting |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine, California, United States | Recruiting |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange, California, United States | Recruiting |
| Mills Health Center | San Mateo, California, United States | Recruiting |
| UF Health Cancer Institute - Gainesville | Gainesville, Florida, United States | Recruiting |
| Miami Cancer Institute | Miami, Florida, United States | Recruiting |
| Memorial Hospital West | Pembroke Pines, Florida, United States | Recruiting |
| Phoebe Putney Memorial Hospital | Albany, Georgia, United States | Recruiting |
| Saint Luke's Cancer Institute - Boise | Boise, Idaho, United States | Recruiting |
| Kootenai Health - Coeur d'Alene | Coeur d'Alene, Idaho, United States | Recruiting |
| Saint Luke's Cancer Institute - Fruitland | Fruitland, Idaho, United States | Recruiting |
| Saint Luke's Cancer Institute - Meridian | Meridian, Idaho, United States | Recruiting |
+ 131 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06577441